Addictions Therapeutics Market Report 2026

The addictions therapeutics market size has grown strongly in recent years. It will grow from $7.46 billion in 2025 to $7.93 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing prevalence of substance use disorders, rising awareness about addiction treatment, growing number of specialized treatment centers, adoption of buprenorphine and naltrexone therapies, expansion of hospital and clinical networks.

The addictions therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.24 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to development of novel addiction therapeutics, increasing government and private funding for suds programs, growth in telehealth and digital treatment platforms, rising integration of mental health and addiction therapies, expansion of public-private partnerships in addiction care. Major trends in the forecast period include rising demand for medication-assisted treatment (mat), expansion of inpatient and outpatient addiction treatment centers, increasing adoption of telehealth and remote counseling services, growing focus on nicotine and opioid addiction therapies, enhanced awareness programs for substance use disorders.

Increasing consumption of alcohol is expected to drive the growth of the addiction therapeutics market going forward. Alcohol consumption refers to the intake of beverages containing ethyl alcohol. Addiction therapeutics are used to treat alcohol dependence by helping individuals reduce alcohol intake, restoring the balance between excitatory and inhibitory neurotransmitters such as glutamate and gamma-aminobutyric acid, which diminishes alcohol cravings and alleviates withdrawal symptoms including insomnia, anxiety, and restlessness. For instance, in December 2024, according to Kirin Holdings Co. Ltd., a Japan-based beverage and pharmaceuticals company, global beer consumption in 2023 increased slightly by approximately 200,000 kl compared to 2022, reaching around 187.9 million kl, equivalent to roughly 296.9 billion 633 ml bottles, marking a modest year-over-year growth of 0.1%. Therefore, rising alcohol consumption is fueling the growth of the addiction therapeutics market.

Major companies operating in the addiction therapeutics market are focusing on developing innovative products, such as drugs for cocaine use disorders (CUD), to reach larger patient populations, increase sales, and expand revenue. Drugs for cocaine use disorders are designed to assist individuals struggling with cocaine addiction by targeting the neurobiological pathways involved in dependence. For instance, in January 2023, Tempero Bio, a US-based biopharmaceutical company, announced FDA approval for TMP-301. This investigational candidate functions as a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM), specifically aimed at treating cocaine use disorders. TMP-301 is notable for its potency, selectivity, and oral availability, designed to counteract overactive glutamate signaling associated with CUD.

In March 2023, Indivior, a US-based pharmaceutical company, acquired Opiant Pharmaceuticals Inc. for approximately $145 million. This acquisition allows Indivior to strengthen its portfolio in investigational opioid overdose therapies and expand its research and treatment offerings in addiction. Opiant Pharmaceuticals Inc. is a US-based biopharmaceutical company specializing in medicines for addiction and drug overdose.

Major companies operating in the addictions therapeutics market are Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Perrigo Company plc, Purdue Pharma L.P., Dr. Reddy's Laboratories Ltd., Cipla Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., Mallinckrodt Plc, Alkermes plc., Glenmark Pharmaceuticals Limited, Indivior plc., Lannett Company Inc., BioDelivery Sciences International Inc., Camurus AB, Orexo AB, Elite Pharmaceuticals Inc., Braeburn Inc., Titan Pharmaceuticals Inc., BioCorRx Inc.

North America was the largest region in the addictions therapeutics market in 2025. The regions covered in the addictions therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the addictions therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the addictions therapeutics market by increasing costs for imported drugs, medical devices, and therapeutic equipment used in treatment centers. Segments such as buprenorphine, naltrexone, and other specialized addiction drugs are most impacted, particularly in north america, europe, and asia-pacific regions. This has led to higher treatment costs and supply chain challenges. On the positive side, tariffs are driving local drug production, innovation in cost-effective therapeutics, and development of domestic treatment infrastructure.

The addictions therapeutics market research report is one of a series of new reports that provides addictions therapeutics market statistics, including addictions therapeutics industry global market size, regional shares, competitors with a addictions therapeutics market share, detailed addictions therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the addictions therapeutics industry. This addictions therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Addiction therapeutics refers to the use of medications, treatments, and management strategies for various forms of addiction, aimed at helping individuals overcome substance use disorders (SUDs) and other addictive behaviors. It includes both group and individual therapy sessions to prevent substance misuse.

The main addiction therapeutics include buprenorphine, naltrexone, bupropion, disulfiram, nicotine replacement products, varenicline, and others. Buprenorphine is a semi-synthetic narcotic analgesic provided in the form of C29H41NO4HCl, used to replicate the effects of opioid medications and prevent withdrawal symptoms when an individual discontinues opioid use. The treatment types include opioid addiction treatment, alcohol addiction treatment, nicotine addiction treatment, and other substance addiction treatments, which are applied in various centers such as inpatient treatment centers, residential treatment centers, and outpatient treatment centers. These therapeutics are distributed through multiple channels, including hospital pharmacies, medical stores, and others, and are used in public, private, and government settings.

The addiction therapeutics market consists of revenues earned by entities by providing cognitive behavioral therapy, contingency management for addiction, rational emotive behavior therapy (REBT), motivational interviewing, family therapy for addiction, facilitation therapy for addiction, eye movement desensitization and reprocessing (EMDR), dialectical behavior therapy, matrix model for addiction and person-centered therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The addiction therapeutics market also includes sales of suboxone, methadone, naltrexone, antidepressants, and acamprosate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.